1 Hyperinflammatory ARDS is characterized by interferon-stimulated gene expression, T-cell 2 activation, and an altered metatranscriptome in tracheal aspirates

**Authors**: Aartik Sarma<sup>1</sup>, Stephanie A. Christenson<sup>1</sup>, Beth Shoshana Zha<sup>1</sup>, Angela Oliveira Pisco<sup>2</sup>, Lucile P.A. Neyton<sup>1</sup>, Eran Mick<sup>2,3</sup>, Pratik Sinha<sup>4</sup>, Jennifer G. Wilson<sup>5</sup>, Farzad Moazed<sup>1</sup>,

Aleksandra Leligdowicz<sup>6,7</sup>, Manoj V. Maddali<sup>8</sup>, Emily R. Siegel<sup>9</sup>, Zoe Lyon<sup>9</sup>, Hanjing Zhou<sup>1</sup>,

3

4

5

6

Alejandra Jauregui<sup>1</sup>, Rajani Ghale<sup>1</sup>, Saharai Caldera<sup>2</sup>, Paula Hayakawa Serpa<sup>2,3</sup>, Thomas 7 Deiss<sup>1</sup>, Christina Love<sup>2</sup>, Ashley Byrne<sup>2</sup>, Katrina L. Kalantar<sup>2</sup>, Joseph L. DeRisi<sup>2</sup>, David J. 8 Erle<sup>6,10,11,12</sup>, Matthew F. Krummel<sup>11,13</sup>, Kirsten N. Kangelaris<sup>14</sup>, Carolyn M. Hendrickson<sup>15</sup>, 9 Prescott G. Woodruff<sup>1,6</sup>, Michael A. Matthay<sup>1,6,16</sup>, COMET Consortium, Charles R. Langelier<sup>2,3</sup>, 10 Carolyn S. Calfee<sup>1,6,16</sup> 11 12 1. Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of 13 Medicine, University of California San Francisco, CA 14 2. Chan Zuckerberg Biohub, San Francisco, CA 15 3 Division of Infectious Diseases, Department of Medicine, University of California San 16 Francisco, CA 17 4. Department of Anesthesia, Washington University in St Louis 18 5. Department of Emergency Medicine, Stanford University School of Medicine, Stanford 19 University, Stanford, CA 20 6. Cardiovascular Research Institute, University of California San Francisco, CA 21 Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, 7. 22 Ontario, Canada 23 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, 8. 24 Stanford University, Stanford, CA 25 School of Medicine, University of California San Francisco, CA 9. 26 10. Lung Biology Center, University of California San Francisco, CA 27 11. Bakar ImmunoX Initiative, University of California San Francisco, CA 28 12. UCSF CoLabs, University of California San Francisco, CA 29 13. Department of Pathology, University of California San Francisco, CA 30 14. Division of Hospital Medicine, University of California San Francisco, CA 31 15. Division of Pulmonary and Critical Care Medicine. Department of Medicine. Zuckerberg 32 San Francisco General Hospital and Trauma Center, University of California San 33 Francisco 34 16. Department of Anesthesia, University of California San Francisco, CA 35 36 Funding: F32HL151117 (AS), R35HL140026 (CSC), 2R24AA019661-06A1 (CSC), NIH/NHLBI 37 K23HL138461-01A1 (CRL), U19 AI1077439 (DJE, CSC), UCSF ImmunoX CoLabs, Chan 38 Zuckerberg Foundation 2019-202665, Genentech TSK-020586 39 40 Abstract: Two molecular phenotypes of the acute respiratory distress syndrome (ARDS) with

41 substantially different clinical trajectories have been identified. Classification as

42 "hyperinflammatory" or "hypoinflammatory" depends on plasma biomarker profiling. Differences

in the biology underlying these phenotypes at the site of injury, the lung, are unknown. We

44 analyze tracheal aspirate (TA) transcriptomes from 46 mechanically ventilated subjects to

45 assess differences in lung inflammation and repair between ARDS phenotypes. We then

46 integrate these results with metatranscriptomic sequencing, single-cell RNA sequencing, and

47 plasma proteomics to identify distinct features of each ARDS phenotype. We also compare

48 phenotype-specific differences in gene expression to experimental models of acute lung injury

49 and use an *in silico* analysis to identify candidate treatments for each phenotype. We find that

50 hyperinflammatory ARDS is associated with increased integrated stress response and interferon

51 gamma signaling, distinct immune cell polarization, and differences in microbial community

52 composition in TA. These findings demonstrate that each phenotype has distinct respiratory

53 tract biology that may be relevant to developing effective therapies for ARDS.

54

55 **Word count**: 3,994

#### 56 57 **COMET Consortium:**

K. Mark Ansel<sup>17,18</sup>, Yumiko Abe-Jones<sup>14</sup>, Saurabh Asthana<sup>11,13</sup>, Alexander Beagle<sup>19</sup>, Sharvari 58

59

Bhide<sup>15</sup>, Cathy Cai<sup>20</sup>, Sidney A. Carrillo<sup>1</sup>, Suzanna Chak<sup>1</sup>, Vincent Chan<sup>11,13,18</sup>, Nayvin Chew<sup>11,12,13,21</sup>, Zachary Collins<sup>11,13</sup>, Alexis Combes<sup>11,12,13,21</sup>, Tristan Courau<sup>11,12,13,21</sup>, Spyros Darmanis<sup>22</sup>, Catherine DeVoe<sup>3</sup>, Gabriela K. Fragiadakis<sup>11,12,23</sup>, Kamir Hiam<sup>2,18,20,24,25</sup>, Kenneth 60 61

Hu<sup>11,13,21</sup>, Billy Huang<sup>26</sup>, Norman Jones<sup>27</sup>, Nitasha Kumar<sup>27</sup>, Divya Kushnoor<sup>11,12,13,21</sup>, Tasha 62

63

Lea<sup>13</sup>, Deanna Lee<sup>6,15</sup>, David Lee<sup>11,23,28</sup>, Yale Liu<sup>19</sup>, Salman Mahboob<sup>26</sup>, Jeff Milush<sup>27</sup>, Priscila Muñoz-Sandoval<sup>17,18</sup>, Viet Nguyen<sup>6,15</sup>, Randy Parada<sup>26</sup>, Ravi Patel<sup>11,12</sup>, Maira Phelps<sup>2</sup>, Logan 64

Pierce<sup>14</sup>, Priya Prasad<sup>14</sup>, Arjun Rao<sup>11,13</sup>, Sadeed Rashid<sup>20</sup>, Gabriella Reeder<sup>11,12,29</sup>, Nicklaus 65

Rodriguez<sup>20</sup>, Bushra Samad<sup>11,13</sup>, Cole Shaw<sup>11,12</sup>, Alan Shen<sup>11,12,13,21</sup>, Austin Sigman<sup>1</sup>, Matthew 66

Spitzer<sup>2,18,20,24,25</sup>, Yang Sun<sup>23</sup>, Sara Sunshine<sup>30</sup>, Kevin Tang<sup>20</sup>, Luz Torres Altamirano<sup>20</sup>, 67 Alexandra Tsitsiklis<sup>3</sup>, Jessica Tsui<sup>11,12,13,21</sup>, Alyssa Ward<sup>23</sup>, Andrew Willmore<sup>1</sup>, Michael Wilson<sup>31</sup>, 68

Juliane Winkler<sup>20</sup>, Kristine Wong<sup>20</sup>, Jimmie Ye<sup>2,23,25,28,32,33</sup>, Michelle Yu<sup>1</sup>, Wandi Zhu<sup>17,18</sup> 69

- 70 17. Sandler Asthma Basic Research Center, University of California San Francisco, CA 71 18. Department of Microbiology and Immunology, University of California San Francisco, CA
- 72 19. Department of Medicine, University of California San Francisco, CA
- 73 20. Helen Diller Family Comprehensive Cancer Center, University of California San 74 Francisco, CA
- 75 21. Department of Anatomy, University of California San Francisco, CA
- 76 22. Microchemistry, Proteomics and Lipidomics Department, Genentech Inc, 1 DNA Way, 77 South San Francisco, CA, 94080
- 78 23. Division of Rheumatology, Department of Medicine, University of California San 79 Francisco, CA
- 80 24. Department of Otolaryngology, University of California San Francisco, CA
- 81 25. Parker Institute for Cancer Immunotherapy, San Francisco, CA
- 82 26. Department of Orofacial Sciences, School of Dentistry, University of California San 83 Francisco, CA
- 84 27. Core Immunology Laboratory Division of Experimental Medicine, University of California 85 San Francisco, CA
- 86 28. Institute for Human Genetics, University of California San Francisco, CA
- 87 29. Biomedical Sciences Graduate Program, University of California San Francisco, CA
- 88 30. Department of Biochemistry and Biophysics, University of California San Francisco, CA
- 89 31. Weill Institute for Neurosciences, Department of Neurology, University of California San 90 Francisco
- 91 32. Department of Epidemiology and Biostatistics, University of California San Francisco, 92 CA
- 93 33. Institute of Computational Health Sciences, University of California San Francisco, CA
- 94

## 95 Introduction

96 The acute respiratory distress syndrome (ARDS) is a clinical condition characterized by 97 noncardiogenic pulmonary edema and hypoxemia within one week of a physiologic insult<sup>1</sup>. This 98 broad clinical definition encompasses a heterogeneous population of critically ill patients. 99 including those with direct pulmonary injury from pneumonia or aspiration and those with 100 indirect pulmonary injury caused by dysregulated systemic inflammation from sepsis. 101 pancreatitis, or trauma. The global incidence of ARDS has surged during the COVID-19 102 pandemic, increasing the importance of finding effective treatments. While some pharmacologic 103 treatments have decreased mortality in mechanically ventilated patients with COVID-19<sup>2,3</sup>, no 104 drug has consistently reduced mortality in more typical heterogeneous cohorts of patients with 105 ARDS. There is a growing recognition that biological heterogeneity within the syndrome is a 106 significant barrier to identifying effective treatments<sup>4</sup>. 107 Two clinically distinct molecular phenotypes of ARDS (termed "hyperinflammatory" and 108 "hypoinflammatory") have been identified using latent class analysis of clinical and plasma 109 biomarker data in five clinical trial cohorts and three observational studies<sup>1,5–11</sup>. The 110 hyperinflammatory phenotype is characterized by elevated plasma inflammatory cytokines (IL-8, 111 IL-6, TNFr-1), lower plasma Protein C and bicarbonate, and higher 90-day mortality compared 112 to the hypoinflammatory phenotype. Differences between phenotypes are not primarily 113 explained by the physiologic insult that caused ARDS (e.g. sepsis, pneumonia, aspiration of 114 gastric contents). Importantly, significant differences in treatment response to simvastatin, 115 ventilator settings, and fluid management have been observed across molecular phenotypes in 116 retrospective analyses of three ARDS clinical trials<sup>5-7</sup>: further, in patients with COVID-19-related 117 ARDS, hyperinflammatory patients may preferentially respond to corticosteroid treatment<sup>12,13</sup>. 118 These results suggest that understanding and targeting the heterogeneous biology underlying 119 ARDS molecular phenotypes is essential to identifying effective new treatments for ARDS. 120 Prospective studies designed to identify these phenotypes using parsimonious models are 121 laying the groundwork for precision clinical trials<sup>4,14</sup>.

Despite this exciting progress, a critical barrier to developing new therapies for ARDS is our superficial understanding of the biological pathways characterizing each phenotype. This knowledge gap was recently cited by an NHLBI workshop on precision medicine in ARDS as a top research priority for the field<sup>4</sup>. To date, analyses of the biological differences between these phenotypes have been limited to circulating biomarkers in plasma or blood, largely due to the relative ease of sampling. Understanding the biological differences between ARDS phenotypes in the lung will be critical to development of informative pre-clinical models of disease and

- 129 targeted treatments for ARDS. Here, we employ a systems biology approach incorporating bulk
- 130 and single-cell RNA-sequencing, metagenomics, and proteomics to understand differences in
- 131 lung immunology, microbiology, and systemic inflammatory responses between ARDS
- 132 phenotypes.
- 133
- 134 **Results**

# 135 Patient enrollment and ARDS phenotype assignment

136 To determine if previously identified ARDS phenotypes are associated with differences 137 in pulmonary biology, we first studied tracheal aspirates (TA) collected from the Acute Lung 138 Injury in Critical Illness study, a prospective, observational cohort of mechanically ventilated 139 patients admitted to the ICU at the University of California San Francisco Medical Center 140 (UCSFMC). Patients were enrolled in this cohort from July 2013 until March 2020, when 141 enrollment was paused due to the COVID-19 pandemic. 77 out of 323 participants had ARDS in 142 this cohort (Supplementary Figure 1). TA host sequencing was available for 41 of the ARDS 143 participants. In addition, we had TA sequencing from five participants who were intubated for 144 neurologic injury, had no evidence of pulmonary disease on chest x-ray (CXR), and were not 145 immunosuppressed. We used a previously validated three-variable classifier model to determine 146 ARDS molecular phenotype based on plasma IL-8, bicarbonate, and Protein C levels<sup>14</sup>. When 147 plasma biomarkers were unavailable from the day of TA collection (n=5), we used a recently 148 described and validated machine learning model to assign phenotype<sup>11,15</sup>. 10 out of 41 ARDS 149 subjects (24%) had hyperinflammatory ARDS, which is consistent with the proportion of 150 hyperinflammatory subjects observed in previous studies<sup>5–9</sup>. There were four extrapulmonary 151 fungal infections (two C. albicans, one C. glabrata, and one H. capsulatum) in the 152 hyperinflammatory phenotype vs. zero in the hypoinflammatory phenotype (p < 0.01, Table 1). 153 There were no significant differences in patient age, sex, BMI, immunosuppression, or ARDS 154 risk factors between the groups. 155

# 156 **TA RNASeq identifies increased pro-inflammatory cytokine signaling and increased**

157 stress response in hyperinflammatory ARDS

We sequenced TA using established methods<sup>16</sup> and used *DESeq2*<sup>17</sup> and *apegIm*<sup>18</sup> to compare TA gene expression between ARDS molecular phenotypes. 1,334 genes (7% of all protein-coding genes) were differentially expressed between ARDS phenotypes at a false detection rate (FDR) <0.1 and absolute empirical Bayesian posterior log<sub>2</sub>-fold change >0.5 (Supplementary Figure 2A, Supplementary Data 1A).

We next used Ingenuity Pathway Analysis (IPA)<sup>19</sup> Upstream Regulator analysis to 163 164 analyze differentially expressed genes. This analysis predicts whether measured gene 165 expression is consistent with activation or inhibition of upstream regulators of gene expression, 166 which include cytokines, receptors, transcription factors, enzymes, endogenous chemicals, and 167 drugs. IPA predicted increased activation of several cytokines and other upstream regulators of 168 differentially expressed genes in hyperinflammatory ARDS (Figure 1.A.i, Supplementary Data 169 2A). Predicted upstream regulators included several pro-inflammatory cytokines that were 170 previously found to be elevated in plasma of patients with hyperinflammatory ARDS, including 171 IL1B, IL6, and TNF. In addition, IPA identified activation of several cytokines that were not 172 previously associated with hyperinflammatory ARDS, including several interferons; IL2 and IL15, which stimulate cytotoxic T cell and NK cell responses<sup>20</sup>; and the chemokine ligand 173 174 CCL2/MCP-1. In addition, upstream regulator analysis predicted increased activation of the 175 integrated stress response (XBP1, NFE2L2), T cell activation (CD3, CD28), stimulation of Toll-176 like receptors (TLR2, TLR3, TLR4, TLR7, TLR9), a metabolic shift to glycolysis (MLXILP), and 177 increased cellular differentiation (MYC, NONO) in hyperinflammatory ARDS (Figure 1.A.ii-iv, 178 Supplementary Data 2A). Because there was a significant difference in fungal infections 179 between phenotypes, we performed a sensitivity analysis adjusting for systemic fungal 180 infections. 997 genes were differentially expressed between phenotypes (711 genes overlapped 181 with the unadjusted analysis), and pathway anlaysis identified similar upstream regulators of 182 gene expression (Supplementary Figure 2, Supplementary Data 1B, Supplementary Data 2B). 183 Together, these analyses identify several novel pathways that are differentially regulated 184 between ARDS molecular phenotypes and support the hypothesis that previously described 185 differences in systemic inflammation are associated with marked differences in respiratory tract 186 biology

187 To further understand how pathways in each phenotype were dysregulated compared to 188 mechanically ventilated lungs, we next performed differential expression and pathway analyses 189 comparing each phenotype to five mechanically ventilated control samples (Figure 1B and 1C, 190 Supplementary Data 1C and 1D). 2,989 genes (15% of protein-coding genes) were differentially 191 expressed between hyperinflammatory ARDS participants and controls, while 2,132 genes 192 (11% of all protein-coding genes) were differentially expressed between hypoinflammatory 193 ARDS and controls. Notably, this analysis identified several cytokines that were activated in 194 both hyperinflammatory ARDS and hypoinflammatory ARDS compared to controls, including 195 IL1B, TNF, and IFNG. While this analysis identified some similarities between phenotypes, we 196 also identified several upstream regulators that were only significantly upregulated in

hyperinflammatory ARDS (Supplementary Data 2C and 2D), including IL-17C, a member of the
 IL-17 family secreted by airway epithelial cells<sup>21</sup>; several Type I/Type III interferons; FAS, which
 stimulates apoptosis<sup>22</sup>; TICAM/MyD88 signaling, which are downstream effectors of Toll-like

200 receptors<sup>23,24</sup>; and the T-cell receptor, suggesting these pathways play a role in the distinct

- 201 biology of hyperinflammatory ARDS.
- 202

# 203 LPS models of acute lung injury replicate gene expression in hyperinflammatory ARDS

204 Upstream regulator analysis identified LPS, a component of Gram-negative bacteria, as 205 a candidate upstream regulator of genes differentially expressed between ARDS phenotypes 206 (Supplementary Data 2A). LPS was also identified as an upstream regulator of gene expression 207 in comparisons of each ARDS phenotype to controls (Supplementary Data 2B, Supplementary Data 2C). LPS is a potent stimulator of NF-kB signaling via TLR4 and MvD88<sup>25</sup> and is frequently 208 used in experimental models of acute lung injury (ALI)<sup>26</sup> thus, we hypothesized that genes 209 210 upregulated in experimental models of lung injury would be enriched in genes that were 211 upregulated in hyperinflammatory ARDS compared to controls but would be relatively less 212 enriched in genes upregulated in hypoinflammatory ARDS compared to controls. Respiratory 213 tract gene expression data was available from four LPS models of ARDS in the Gene 214 Expression Omnibus. We also identified 17 more datasets from other experimental models of 215 ARDS including ventilator-induced lung injury (VILI), ozone, hyperoxia, Pam3Cys (a TLR2 216 agonist), and hemorrhagic shock (Supplementary Data 3A). We used GEO2Enrichr<sup>27</sup> to identify 217 gene sets that were differentially expressed in lung injury compared to controls in experimental 218 models. We then used *gsva* to calculate a expression score for each of these gene sets in TA 219 samples and used *limma* to compare expression of these gene sets in each ARDS phenotype to 220 controls (Figure 1D, Supplementary Data 3B and 3C). Gene sets from four models were 221 significantly enriched (FDR < 0.1) in TA from both ARDS phenotypes. As expected, LPS models 222 had a significant overlap with both phenotypes, but LPS experimental gene sets had higher 223 GSVA scores in hyperinflammatory participants. In addition, gene sets from five experimental 224 models (two ozone models, two LPS models, and one VILI model) were enriched in 225 hyperinflammatory ARDS, but were not enriched in hypoinflammatory ARDS, suggesting these 226 models better replicate dysregulated gene expression observed in the hyperinflammatory 227 phenotype. 228

- 220
- 229

# 230 Transcriptomes identify candidate drugs for hyperinflammatory ARDS

231 To identify candidate treatments for each ARDS phenotype, we next used IPA's 232 Upstream Regulator Analysis to identify drugs that were predicted to shift gene expression from 233 each ARDS phenotype toward control subjects. This approach has been used to identify drugs 234 that can be tested in experimental models and clinical systems, and we have previously used 235 this approach to identify candidate treatments for COVID-19 ARDS.<sup>16,28</sup> This *in silico* analysis 236 identified several drugs predicted to shift gene expression in the hyperinflammatory phenotype 237 toward ventilated controls (Figure 1.E.i, Supplementary Data 2B), while fewer drugs were 238 predicted to shift gene expression in hypoinflammatory ARDS toward controls (Figure 1.E.ii, 239 Supplementary Data 2C). Interestingly, our analysis also identified drugs predicted to shift gene 240 expression from control mechanically ventilated patients toward ARDS phenotypes. For 241 example, nitrofurantoin, amiodarone, and cytarabine, all of which cause drug-induced 242 pneumonitis, were predicted to shift gene expression from controls toward the 243 hyperinflammatory phenotype (Figure 1.E.ii). 244 245 TA immune cells are distinctly polarized in hyperinflammatory ARDS 246 To identify the sources of differential gene expression identified in bulk RNA sequencing 247 data, we used a neutrophil-preserving single-cell RNA sequencing (scSeq) pipeline to study TA 248 from eight COVID-negative patients with ARDS enrolled in a separate prospective, 249 observational cohort, the COVID-19 Multiphenotyping for Effective Therapies (COMET) study. 250 TA scSeq was available from six participants with hypoinflammatory ARDS and two participants 251 with hyperinflammatory ARDS. 18,717 cells passed quality control filters (3,782 from 252 hyperinflammatory ARDS, Figure 2A). We determined cell identities using SingleR<sup>29</sup> to compare 253 cell transcriptomes to signatures derived from the Human Primary Cell Atlas (Figure 2B). 254 Neutrophils were the most common cell type identified in TA from both phenotypes (48% of 255 hyperinflammatory TA cells and 36% of hypoinflammatory TA cells, Figure 2C), which 256 highlighted the importance of using neutrophil-preserving methods to study ARDS phenotypes. To identify cell-specific differences between ARDS phenotypes, we used MAST to fit 257 mixed effects models of differential gene expression (FDR < 0.1)<sup>30</sup>. To address 258 259 pseudoreplication bias and account for within-subject correlation in gene expression<sup>31</sup>, we 260 modeled ARDS phenotype as a fixed effect and each subject as a random effect. 231 genes 261 were differentially expressed between phenotypes in TA neutrophils (Figure 2.D.i, 262 Supplementary Data 4A). CCL2/MCP-1, which synergistically promotes neutrophil migration 263 with IL-8 and is elevated in bronchoalveolar lavage (BAL) fluid from LPS-challenged volunteers

264 and patients with ARDS<sup>32</sup>, was identified as an upstream regulator of neutrophil gene 265 expression in hyperinflammatory ARDS (Figure 2.D.ii, Supplementary Data 5A). In addition, 266 upstream regulator analysis predicted increased activaton of MYC, a key mediator of 267 granulopoiesis<sup>33</sup>, and MLXIPL, which promotes glycolysis<sup>34</sup>, in hyperinflammatory neutrophils 268 (Figure 2.D.iii, Supplementary Data 5A). Notably, increased glycolytic activity has previously been reported in LPS-stimulated neutrophils<sup>35</sup>. In contrast to our bulk RNASeg analysis, 269 270 upstream regulator analysis predicted relatively higher activation of several proinflammatory 271 cytokines, including TNF, IL6, and IFNG, in hypoinflammatory neutrophils. 272 Next, we investigated differences in monocytes and macrophages in ARDS phenotypes. 273 189 genes were differentially expressed between 690 hyperinflammatory monocytes and 274 3802 hypoinflammatory monocytes (Figure 2.E.i, Supplementary Data 4B) while 339 genes 275 were differentially expressed in 296 monocyte-derived macrophages (MDM) from 276 hyperinflammatory ARDS and 1,930 MDM from hypoinflammatory ARDS (Figure 2.F.i, 277 Supplementary Data 4C). Only 15 genes were differentially expressed in alveolar macrophages 278 (Supplementary Data 4D), which was insufficient for pathway analysis and suggested these 279 cells played less of a role in differences between ARDS phenotypes. As in the neutrophils, IPA 280 predicted relatively higher activation of several pro-inflammatory cytokines in hypoinflammatory 281 ARDS, including TNF, IL1B, and IFNG, in monoctyes and MDM, while two canonical Type 2 282 cytokines, IL4 and IL13, were predicted to be activated in hyperinflammatory ARDS for both cell 283 types (Figure 2.E.ii and 2.F.ii, Supplementary Data 5B and 5C). As in the bulk RNASeq data, we 284 observed higher activation of NFE2L2, which protects against oxidative stress and inhibits the NLRP3 inflammasome<sup>37</sup> in monoctyes and MDM from hyperinflammatory ARDS (Figure 2.E.iii 285 286 and Figure 2.F.iii).

287 We next compared gene expression in T cells and found 281 genes that were 288 differentially expressed between 477 T cells from hyperinflammatory ARDS and 1.665 T cells 289 from hypoinflammatory ARDS (Figure 2.G.i, Supplementary Data 4E). IPA identified activation 290 expression of interferon, TLR4, and NF-KB stimulated genes in T cells from the 291 hyperinflammatory phenotype (Figure 2.G.ii, Supplementary Data 5D), which was consistent 292 with the pattern observed in bulk RNA sequencing and suggested these T cells were T<sub>h</sub>1 293 polarized. IPA also predicted increased activation of cell differentiation markers (NONO) and 294 activation of the integrated stress response (XBP1, EIF2AK2) in T cells from the 295 hyperinflammatory phenotype (Figure 2.G.iii, Supplementary Data 5D). We used *connectome*<sup>38</sup>, which compares single-cell gene expression to the FANTOM5 296 297 ligand-receptor database<sup>39</sup>, to identify ligand-receptor pairs in lower respiratory cells that were

unique to each ARDS phenotype (Supplementary Data 6A and 6B). Several ligand-receptor
pairs were observed in hyperinflammatory ARDS but were not present in hypoinflammatory
ARDS (Supplementary Figure 3). For example, *IFNG* from T and NK cells and *IFNGR2* on MDM
were identified as a distinct ligand-receptor pair in hyperinflammatory ARDS, suggesting these
cells play a key role in the dysregulated pathways identified in bulk and single-cell differential
expression analyses. Together, our scSeq analyses confirm that TA immune cells have distinct
transcriptomic profiles in each ARDS phenotype.

305

# 306 Plasma proteomic analysis identifies additional cytokines that are upregulated in307 hyperinflammatory ARDS

308 To further validate the biologic relevance of the TA findings, we used the O-Link Target 309 96 Inflammation panel to measure plasma protein biomarker concentrations. 21 participants 310 included in the TA bulk sequencing analysis also had plasma O-link data available. In addition, 311 proteomic data was available for four participants from the same cohort who did not have TA 312 bulk sequencing available for analysis. Of the 25 included participants, five had 313 hyperinflammatory ARDS and 20 had hypoinflammatory ARDS. We also measured plasma 314 protein concentrations in 14 healthy volunteers on the same O-link plate. 315 Plasma concentrations of 28 proteins were higher in hyperinflammatory ARDS than in 316 hypoinflammatory ARDS (FDR < 0.1, Figure 3A). Some of these biomarkers confirmed known 317 differences between phenotypes, including higher concentrations of IL6 and TNF in 318 hyperinflammatory ARDS. In addition, we identified nine plasma protein biomarkers notably 319 higher in hyperinflammatory ARDS over controls (Figure 3B) but not higher in hypoinflammatory 320 ARDS compared to controls (Figure 3C), suggesting they identify distinctly dysregulated 321 pathways in the hyperinflammatory phenotype. These proteins included IL-8, which is one of the 322 cytokines that defines the hyperinflammatory phenotype: CASP-8, an effector of FAS signaling<sup>40</sup>; the interferon gamma (IFNy) induced proteins CXCL9 and CXCL10<sup>41</sup>; plasma 323 324 urokinase (uPA); oncostatin M; and adenosine deaminase (ADA). In addition, CCL2/MCP-1 and the T cell activation marker CD5<sup>42</sup> were higher in hyperinflammatory ARDS and in controls 325 326 compared to hypoinflammatory ARDS. These observations were consistent with observed 327 differences in TA gene expression at both the bulk RNASeg and scSeg level, particularly 328 increased CCL2 and FAS activity, IFNy-stimulated gene expression, and T cell activation in 329 hyperinflammatory ARDS. 330

- 550
- 331

## 332 Phenotypes were associated with differences in the respiratory microbiome

333 Because our analyses demonstrated significant differences in host respiratory tract 334 biology in each phenotype, we hypothesized that each phenotype would have a distinct 335 respiratory microbiome that could stimulate a dysregulated response. We used a previously 336 described metagenomic sequencing pipeline to align non-human sequences in TA sequencing to microbial genomes<sup>43</sup> and used established methods to filter background contamination from 337 338 samples<sup>44</sup>. Taxa were aggregated at the genus level for downstream analyses. There was no 339 significant difference in alpha diversity between phenotypes for all microbial taxa, bacteria, or 340 fungi (Figure 4A). There was a significant difference in microbial community composition 341 between phenotypes (Bray-Curtis distance, PERMANOVA p = 0.001, Figure 4B). This 342 difference was not significant when the analysis was restricted to bacterial taxa (p = 0.117, 343 Figure 4C), but was significant when the analysis was restricted to fungal taxa (p = 0.004. 344 Figure 4D). We next compared differential abundance of microbial transcripts using 345 metagenomeSeg<sup>45</sup>. We found increased abundance of Candida in TA from patients with 346 hyperinflammatory ARDS (Figure 4E). In addition, we observed greater abundance of multiple 347 bacterial taxa in the hypoinflammatory phenotype, including *Escherichia*, *Proteus*, and 348 *Citrobacter*, three taxa in the *Enterobactericeae* family, which was associated with an increased risk of ARDS in a cohort of trauma patients<sup>46</sup>. Together, these observations support the 349 350 hypothesis that there is a significant difference in microbial community composition between 351 ARDS phenotypes.

352

## 353 Discussion

354 In this study, we performed an integrated transcriptomic and proteomic analysis of 355 ARDS phenotypes. To our knowledge, this represents the first demonstration of differences in 356 pulmonary biology between molecular phenotypes of ARDS, which have previously been 357 characterized primarily using plasma biomarkers. We identified differences between phenotypes 358 in bulk RNA transcriptomes and used scSeq to identify distinctly polarized immune cells in the 359 TA. In addition, O-Link proteomics identified differences in plasma protein concentrations 360 consistent with these observations. We also found significant differences in the TA microbial 361 community composition between phenotypes. Our findings support the hypothesis that each 362 ARDS phenotype has distinct pulmonary pathobiology and may be more likely to respond to 363 treatments specifically targeting these dysregulated pathways. 364 Here, we find hyperinflammatory ARDS was associated with markedly higher IFNy

365 stimulated gene expression and T cell activation in TA. In bulk RNA sequencing, pathway

366 analysis identified markedly higher expression of IFNy stimulated genes and increased 367 expression of genes stimulated by the T cell receptor. Plasma proteomics identified increased 368 concentrations of the IFNy-stimulated proteins CXCL9 and CXCL10 and the T cell activation 369 marker CD5 in hyperinflammatory ARDS but not in hypoinflammatory ARDS. Notably, in an 370 alternative molecular phenotyping approach that used k-means clustering of plasma biomarkers 371 to categorize ARDS subjects into two molecular phenotypes ("reactive" and "uninflamed"), 372 plasma IFNy is one of the defining biomarkers of the higher mortality "reactive" phenotype<sup>47</sup>. 373 Together, our analyses support a central role of IFNy and T cell activation in hyperinflammatory 374 ARDS.

375 We used scSeq to identify cell-specific differences in immune responses. We found 376 evidence of increased neutrophil migration and differentiation in hyperinflammatory ARDS. 377 MDM from the higher-mortality hyperinflammatory phenotype expressed fewer pro-inflammatory 378 genes, which is consistent with a prior analysis showing decreased pro-inflammatory gene 379 expression in BAL macrophages collected on the day of intubation was associated with increased mortality in a cohort of ARDS patients<sup>48</sup>. In contrast, T cells demonstrated higher 380 381 interferon-stimulated gene expression in hyperinflammatory ARDS. Interestingly, this pattern of 382 high interferon-stimulated gene expression in T cells but diminished immune responses in 383 macrophages has also been reported in severe COVID-19<sup>49</sup>. These findings suggest 384 dysregulated responses to immune signaling in specific cell populations may drive inflammation 385 in hyperinflammatory ARDS.

386 The interplay of the respiratory microbiome, lung injury, and ARDS has long been 387 hypothesized but remains an important knowledge gap in the field. In one experimental study, 388 changes in the respiratory microbiome mediated lung injury<sup>50</sup>, however, a small prior study 389 using 16S sequencing of mini-BAL specimens found no difference in the microbiome 390 composition between phenotypes<sup>51</sup>. Because we used metatransciptomic sequencing, we were 391 able to identify non-bacterial taxa present in TA samples. We identified significant differences in 392 microbial community composition between phenotypes and more transcripts from Candida in 393 hyperinflammatory ARDS. Decreased fungal diversity in the respiratory tract has previously 394 been associated with increased organ dysfunction and shock in patients with ARDS<sup>52</sup>, and an increased burden of BAL Candida is associated with worse outcomes in ventilated patients with 395 396 COVID<sup>53</sup>. Prior studies have also shown an association between *Enterobacteriaceae* and a risk 397 of developing ARDS<sup>46,54</sup>: in our analysis, three genera in *Enterobacteriaceae* (*Escherichia*, 398 *Proteus*, and *Citrobacter*) were more abundant in hypoinflammatory ARDS than 399 hyperinflammatory ARDS. While Candida can stimulate the dysregulated pathways observed in

hyperinflammatory ARDS<sup>55</sup>, further research is required to determine if the respiratory
 microbiome causes (or, alternatively, results from) inflammation in hyperinflammatory ARDS,
 and, if the association is causal, which taxa are responsible for lung injury.

403 We compared differentially expressed genes in clinical samples to experimental ALI 404 models. A prior analysis comparing rodent ALI models to human LPS challenge models found a significant overlap in gene expression between animal and human experimental systems<sup>56</sup>. An 405 406 experimental model combining intratracheal LPS and mechanical ventilation was the murine 407 model with the strongest overlap in gene expression with ARDS subjects in both phenotypes. 408 This gene signature was from an experiment demonstrating that a combined MV/LPS model 409 generated markedly higher neutrophilic inflammation in the lung than LPS or MV alone<sup>57</sup>. These 410 observations suggest a two-hit model reproduces important biological changes observed in 411 ARDS. In addition, gene signatures from five models were enriched in hyperinflammatory ARDS 412 but were not enriched in hypoinflammatory ARDS, suggesting these models did not replicate 413 respiratory tract biology of the latter group. These observations may partially explain why 414 therapies that appear promising in pre-clinical models are not effective in more heterogeneous 415 clinical trial populations.

416 Our results provide further evidence that ARDS molecular phenotypes identify 417 biologically-important differences in immune biology, and have several important implications for 418 developing a precision approach to treating ARDS<sup>4</sup>. Pathway analyses identified different drugs 419 that were predicted to shift gene expression from ARDS toward ventilated controls in each 420 phenotype. These candidate therapies require further investigation in pre-clinical models, and 421 our results also demonstrate that some experimental models are more effective at reproducing 422 changes in gene expression observed in clinical samples in each phenotype. Future preclinical 423 studies and RCTs must account for this biological heterogeneity.

424 Strengths of this study include transcriptomic analysis of samples from the focal organ of 425 injury in ARDS, providing a highly detailed picture of the pulmonary biology of both ARDS 426 phenotypes, and validation of these observations with metatranscriptomics, single-cell 427 sequencing, and peripheral blood proteomics. In addition, the inclusion of non-ARDS ventilated 428 controls allowed us to further characterize the physiologic dysregulation in the phenotypes, 429 rather than defining gene expression relative to another pathologic state. This approach also 430 allowed us to compare our clinical samples to experimental models and identify candidate 431 medications that may be suitable for clinical trials in each phenotype. 432

This analysis also has some limitations. The sample size for each analysis is modest;
however, it was adequately powered to detect large changes in gene expression and protein

434 concentrations. We performed CD45<sup>+</sup> selection for scSeq samples, which allowed us to isolate 435 hematopoietic immune cells, including neutrophils, but selected against epithelial cells, which 436 generate important signals in our bulk RNASeg and plasma protein analyses and likely play a 437 important role in ARDS phenotype biology. In addition, while TA contains fluid from the distal 438 airspaces<sup>58</sup>, and we have previously shown that TA and BAL isolate similar immune cells<sup>16</sup> and 439 microbiota<sup>59</sup>, it is possible that more invasive BAL testing may identify additional differences 440 between the phenotypes. Future analyses should include larger cohorts to replicate these 441 findings and determine if TA sequencing or plasma cytokines more accurately predict clinical 442 trajectory and response to treatment. 443 In conclusion, an integrated, multi-omic analysis of ARDS molecular phenotypes defined 444 by plasma protein biomarkers suggests the hyperinflammatory phenotype is characterized by

445 marked differences in TA gene expression, metagenomics, and plasma proteins. Our findings

suggest the respiratory tract biology of these phenotypes is distinct and further supports the use

of molecular phenotypes to study acute lung injury biology and develop new treatments for

448 ARDS.

|                            | Hyperinflammatory | Hypoinflammatory  | P (1) | Control       | P (2) | Р(3  |
|----------------------------|-------------------|-------------------|-------|---------------|-------|------|
| N                          | 10                | 31                |       | 5             |       |      |
| Age                        | 66 [56, 72]       | 63 [51, 70]       | 0.63  | 66 ± 23       | 0.85  | 0.42 |
| Female                     | 4 (40)            | 21 (68)           | 0.95  | 3 (60)        | 0.26  | 0.49 |
| BMI (kg/m²)                | 25.0 [23.6, 25.6] | 25.9 [23.9, 32.2] | 0.27  | 25.7 ± 4.8    | 0.24  | 0.23 |
| Vasopressors at enrollment | 9 (90)            | 19 (61)           | 0.19  | 1 (20)        | <0.01 | 0.2  |
| IL-8, pg/ml                | 424 [228, 1068]   | 15 [9, 25]        | <0.01 | 10 [8, 11]    | <0.01 | 0.2  |
| Protein C, % control       | 51 [31, 62]       | 103 [76, 132]     | <0.01 | 115 [79, 148] | <0.01 | 0.7  |
| Immunosuppression          | 4 (40)            | 6 (19)            | 0.37  |               |       |      |
| Primary ALI Risk Factor    |                   |                   | 0.79  |               |       |      |
| Pneumonia                  | 4 (40)            | 16 (48)           |       |               |       |      |
| Sepsis                     | 4 (40)            | 7 (23)            |       |               |       |      |
| Aspiration                 | 2 (20)            | 6 (23)            |       |               |       |      |
| Pancreatitis               | 0 (0)             | 1 (3)             |       |               |       |      |
| None                       | 0 (0)             | 1 (3)             |       |               |       |      |
| Clinical microbiology*     |                   |                   |       |               |       |      |
| Respiratory virus          | 1 (10)            | 1 (3)             | 0.98  |               |       |      |
| Respiratory bacteria       | 3 (30)            | 11 (36)           | 1.00  |               |       |      |
| Extrapulmonary bacteria    | 3 (30)            | 5 (16)            | 0.62  |               |       |      |
| Extrapulmonary fungus      | 4 (40)            | 0 (0)             | <0.01 |               |       |      |

449 **Table 1:** Characteristics of patients included in differential expression analysis of ARDS phenotypes from the Acute Lung Injury in

450 Critical Illness cohort. Normally distributed values are reported as mean ± SD. Non-normally distributed values are reported as

451 median [IQR]. Categorical data are reported as N (% of total for category). P-values are for a t-test for normally distributed

452 continuous data, Wilcoxon rank-sum for non-normally distributed, and chi-square test for categorical data. P values are for (1)

453 hyperinflammatory ARDS vs. hypoinflammatory ARDS; (2) hyperinflammatory ARDS vs. controls; (3) hypoinflammatory ARDS vs.

454 controls. \*No subjects in this cohort had a systemic viral infection or respiratory fungal infection.

#### 455 Captions

456

457 Figure 1: Bulk RNA sequencing analyses of TA collected in the Acute Lung Injury in Critical 458 Illness cohort.

459

460 A-C) Differential gene expression and IPA upstream regulator scores in TA. A) 10

461 hyperinflammatory ARDS participants vs. 31 hypoinflammatory ARDS participants. B) 10

462 hyperinflammatory ARDS participants vs. five hypoinflammatory ARDS participants. C) 31

- 463 hypoinflammatory ARDS participants vs. five control participants.
- 464

465 For each comparison; (i) volcano plot of differential gene expression, where the log<sub>2</sub> fold 466 difference is on the x-axis and the -log<sub>10</sub> adjusted p-value is on the y-axis; (ii-iv) IPA upstream 467 regulator z-scores for (ii) cytokines, (iii) transmembrane and nuclear receptors, and (iv) 468 transcription regulators in the IPA database. A maximum of 20 significant upstream regulators 469 are shown for each panel. Redundant upstream regulators (e.g. inteferons or interleukins in the 470 same family) were omitted from the figure. For a complete list of upstream regulator scores, see

- 471 Supplementary Data 2.
- 472

473 D) Gene set variation analysis for experimental models of lung injury. We identified 21 models

- 474 of acute lung injury in the Gene Expression Omnibus and used GEO2Enrichr to identify up to 475 200 genes differentially expressed (FDR < 0.05) in the experimental model compared to
- 476 controls. GSVA scores were calculated for each sample, and the difference between
- 477 hyperinflammatory ARDS and controls (orange) and hypoinflammatory ARDS and controls
- 478 (blue) was estimated with limma. Experimental gene sets that are significantly different from
- 479 controls are shown with solid triangles, while gene sets that are not significant are shown with
- 480 transparent circles. For each model, the GEO Accession Number, organism, and lung injury
- 481 model are listed on the x-axis.
- 482

483 E) IPA Upstream Regulator Analysis scores for selected drugs in the IPA database for (i) 484 hyperinflammatory ARDS vs. controls, and (ii) hypoinflammatory ARDS vs. controls. A positive 485 z-score indicates the drug is predicted to shift gene expression from ventilated lungs toward 486 ARDS lungs, while a negative score indicates the drug is predicted to shift gene expression 487 from ARDS towards controls. Upstream regulators that did not meet statistical significance criteria are displayed using a transparent dot.

488 489

490 Figure 2: Single-cell RNA sequencing from TA in the COMET cohort. A) Seurat UMAP 491 projection of 18,717 TA cell transcriptomes from two participants with hyperinflammatory ARDS

492 and six participants with hypoinflammatory ARDS, annotated with cell type as predicted by

493 SingleR. B) UMAP projection of TA cells transcriptomes separated by ARDS phenotype. C) Bar 494 plot of cell proportions in each phenotype.

- 495

496 D-G) Differential expression and pathway analyses for D) Neutrophils, E) Monocytes, F)

497 Monocyte-derived macrophages, and G) T cells. For each cell type: (i) volcano plot of

498 differential gene expression. A positive fold change indicates the gene is more highly expressed

499 in hyperinflammatory ARDS. (ii) IPA upstream regulator scores for cytokines and (iii) IPA

500 upstream regulator scores for the top 40 non-cytokine regulators of gene expression. A positive

- 501 z-score indicates the cytokine is predicted to be more active in hyperinflammatory ARDS
- 502 compared to hypoinflammatory ARDS.
- 503

504 Figure 3: O-Link proteomics results for plasma biomarkers from 5 hyperinflammatory ARDS, 20 505 hypoinflammatory ARDS, and 14 control participants. Each heatmap shows plasma protein

506 biomarkers that were significantly different between groups (FDR < 0.1); for a complete list of

507 proteins, see Supplementary Data 7. Each column represents an individual subject and each 508 row shows the z-scaled concentrations. Rows and columns are clustered using the Euclidean

508 row shows the z-scaled concentrations. Rows and columns are clustered using the Euclidear 509 distance. Columns are annotated by phenotype (orange is hyperinflammatory, blue is

510 hypoinflammatory, and green is healthy volunteer). Z-score for expression is shown on the color

511 bar on the right, and the scale is the same across all three heatmaps. A) Hyperinflammatory

512 ARDS vs. hypoinflammatory ARDS. B) Hyperinflammatory ARDS vs. healthy volunteers. C)

513 Hypoinflammatory ARDS vs. healthy volunteers.

514

515 **Figure 4**: Results of metatranscriptomic sequencing analyses of TA from 31 subjects with

516 hypoinflammatory ARDS and 10 subjects with hyperinflammatory ARDS from the Acute Lung 517 Injury in Critical Illness cohort. All analyses are performed with metatranscriptomic data

518 aggregated at the genus level. A) Shannon diversity index for each TA sample, shown for all

519 taxa, bacteria, and fungi. Each point represents an individual participant. P-value for Wilcoxon

520 rank-sum test. B-D) Principal components analysis of metatranscriptomic reads mapped to all

521 taxa, bacteria, or fungi in TA. Each point represents an individual subject. Subjects with

522 systemic fungal infections are identified with triangles. Ellipses show the 95% confidence

- interval around the centroid. PERMANOVA for Bray-Curtis dissimilarity was calculated using
   adonis2 in vegan. D) Volcano plot showing differential abundance for TA metatranscriptomes.
- adonis2 in vegan. D) Volcano plot showing differential abundance for TA metatranscriptomes.
   Genera that are significantly higher in hyperinflammatory ARDS are in orange and genera that
- 526 are significantly higher in hypoinflammatory ARDS are in blue.

527

Supplementary data 1: Differential gene expression for pairwise comparisons of bulk RNA
 gene expression for TA in the Acute Lung Injury in Critical Illness cohort. A positive log<sub>2</sub> fold
 difference indicates the gene is more highly expressed in the first group compared to second
 group for each comparison. A) Hyperinflammatory ARDS vs. hypoinflammatory ARDS; B)
 Hyperinflammatory ARDS vs. controls; and C) Hypoinflammatory ARDS vs. controls; and D) All
 ARDS subjects vs. controls.

534

Supplementary data 2: IPA Upstream Regulator scores for pairwise comparisons of bulk RNA
gene expression for TA in the Acute Lung Injury in Critical Illness Cohort. A positive z-score
indicates gene expression is consistent with higher activity of the upstream regulator in the first
group compared to second group for each comparison. A) Hyperinflammatory ARDS vs.
hypoinflammatory ARDS; B) Hyperinflammatory ARDS vs. controls; C) Hypoinflammatory
ARDS vs. controls; and D) All ARDS vs. controls.

541

542 Supplementary data 3: A) 200 most upregulated genes in experimental models of lung injury 543 compared to controls for 21 experimental systems in the Gene Expression Omnibus. B) Gene 544 set enrichment analysis scores and leading edge genes for experimental model gene sets in TA 545 differential expression for hyperinflammatory ARDS vs. controls. C) Gene set enrichment 546 analysis scores and leading edge genes for experimental model gene sets in TA differential 547 expression for hypoinflammatory ARDS vs. controls.

548

Supplementary data 4: Differential gene expression for single-cell RNA sequencing for TA for
 the COMET cohort. A positive log<sub>2</sub> fold difference indicates the gene is more highly expressed in
 hyperinflammatory ARDS. A) Neutrophils, B) Monocytes, C) Monocyte-derived macrophages,
 D) Alveolar macrophages, E) T cells, F) Dendritic cells

554 Supplementary data 5: IPA Upstream Regulator scores for pairwise comparisons of bulk RNA

555 gene expression for TA in the COMET. A positive z-score indicates gene expression is

556 consistent with higher activity of the upstream regulator in the hyperinflammatory ARDS

samples. A) Neutrophils, B) Monocytes, C) Monocyte-derived macrophages, D) T cells, and E)Dendritic cells

559

Supplementary Data 6: Connectome results for ligand-receptor pairs in TA single-cell RNA
 sequencing from the COMET cohort for A) hyperinflammatory ARDS and B) hypoinflammatory
 ARDS.

564 **Supplementary Data 7:** A) Z-scaled O-link protein concentrations for five hyperinflammatory 565 ARDS, 20 hypoinflammatory ARDS, and 14 control subjects. B) Results of Wilcoxon rank-sum 566 tests for pairwise comparisons of hyperinflammatory ARDS, hypoinflammatory ARDS, and 567 control subjects.

- 568
- 569 **Supplementary figure 1:** Subjects included in this analysis.

570 571 **Supplementary figure 2:** Sensitivity analysis for differential gene expression between 572 phenotypes after adjusting for fungal infections. (A) volcano plot of differential gene expression, 573 where the  $\log_2$  fold difference is on the x-axis and the  $-\log_{10}$  adjusted p-value is on the y-axis. 574 (B) Scatter plot showing estimated log<sub>2</sub>-fold difference in gene expression between phenotypes. 575 The log<sub>2</sub>-fold difference in gene expression without adjusting for systemic fungal infections is on 576 the x-axis, and the  $\log_2$ -fold difference in gene expression after adjusting is shown on the y-axis. 577 (C-E) IPA upstream regulator z-scores for (C) cytokines, (D) transmembrane and nuclear 578 receptors, and (E) transcription regulators in the IPA database. A maximum of 20 significant

- 579 upstream regulators are shown for each panel. Redundant upstream regulators (e.g. inteferons 580 or interleukins in the same family) were omitted from the figure. For a complete list of upstream
- 581 regulator scores, see Supplementary Data 2B.

582
 583 Supplementary figure 3: Circos plots showing ligand-receptor pairs that are only significant in
 584 hyperinflammatory ARDS.

585

586 **Supplementary figure 4**: Heatmaps for plasma proteins that are significantly higher in A)

587 Controls vs. hyperinflammatory ARDS and B) Controls vs. hypoinflammatory ARDS

### 588 **References**

- 589 1. Matthay, M. A. et al. Acute respiratory distress syndrome. Nature Reviews Disease Primers
- **5**90 **5**, 1–22 (2019).
- 591 2. Abani, O. et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a
- randomised, controlled, open-label, platform trial. *The Lancet* **397**, 1637–1645 (2021).
- 593 3. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19.
- 594 *New England Journal of Medicine* **384**, 693–704 (2021).
- 595 4. Beitler, J. R. *et al.* Advancing precision medicine for acute respiratory distress syndrome.
- 596 *Lancet Respir Med* S2213-2600(21)00157–0 (2021) doi:10.1016/S2213-2600(21)00157-0.
- 597 5. Calfee, C. S. *et al.* Subphenotypes in acute respiratory distress syndrome: latent class
- analysis of data from two randomised controlled trials. *The Lancet Respiratory Medicine* **2**,
- 599 **611–620 (2014)**.
- 600 6. Famous, K. R. *et al.* Acute respiratory distress syndrome subphenotypes respond differently
- 601 to randomized fluid management strategy. *American Journal of Respiratory and Critical*
- 602 *Care Medicine* **195**, 331 338 (2017).
- 603 7. Calfee, C. S. *et al.* Acute respiratory distress syndrome subphenotypes and differential
- 604 response to simvastatin: secondary analysis of a randomised controlled trial. *The Lancet*
- 605 *Respiratory Medicine* **6**, 691 698 (2018).
- 8. Sinha, P. *et al.* Latent class analysis of ARDS subphenotypes: a secondary analysis of the
- statins for acutely injured lungs from sepsis (SAILS) study. *Intensive Care Medicine* 44,
- 608 **1859–1869 (2018)**.

- 609 9. Sinha, P. *et al.* Latent class analysis-derived subphenotypes are generalisable to
- 610 observational cohorts of acute respiratory distress syndrome: a prospective study. *Thorax*
- 611 (2021) doi:10.1136/thoraxjnl-2021-217158.
- 612 10. Meyer, N. J., Gattinoni, L. & Calfee, C. S. Acute respiratory distress syndrome. *The Lancet*
- 613 **398**, 622–637 (2021).
- 614 11. Maddali, M. V. et al. Validation and utility of ARDS subphenotypes identified by machine-
- 615 learning models using clinical data: an observational, multicohort, retrospective analysis.
- 616 The Lancet Respiratory Medicine (2022) doi:10.1016/S2213-2600(21)00461-6.
- 617 12. Sinha, P. *et al.* Latent Class Analysis Reveals COVID-19–related Acute Respiratory Distress
- 618 Syndrome Subgroups with Differential Responses to Corticosteroids. *Am J Respir Crit Care*
- 619 *Med* **204**, 1274–1285 (2021).
- 620 13. Chen, H. *et al.* Corticosteroid Therapy Is Associated With Improved Outcome in Critically III
- 621 Patients With COVID-19 With Hyperinflammatory Phenotype. *Chest* **159**, 1793–1802 (2021).
- 622 14. Sinha, P. *et al.* Development and validation of parsimonious algorithms to classify acute
- 623 respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled
- 624 trials. *Lancet Respir Med* **8**, 247–257 (2020).
- 15. Sinha, P., Churpek, M. M. & Calfee, C. S. Machine Learning Classifier Models Can Identify
- 626 Acute Respiratory Distress Syndrome Phenotypes Using Readily Available Clinical Data. *Am J*
- 627 *Respir Crit Care Med* **202**, 996–1004 (2020).
- 628 16. Sarma, A. *et al.* Tracheal aspirate RNA sequencing identifies distinct immunological features
   629 of COVID-19 ARDS. *Nat Commun* 12, 5152 (2021).

- 630 17. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for
- 631 RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 632 18. Zhu, A., Ibrahim, J. G. & Love, M. I. Heavy-tailed prior distributions for sequence count data:
- 633 removing the noise and preserving large differences. *Bioinformatics* **35**, 2084–2092 (2019).
- 634 19. Krämer, A., Green, J., Pollard, J. & Tugendreich, S. Causal analysis approaches in Ingenuity
- 635 Pathway Analysis. *Bioinformatics* **30**, 523–530 (2014).
- 636 20. Waldmann, T. A. The biology of interleukin-2 and interleukin-15: implications for cancer
- therapy and vaccine design. *Nat Rev Immunol* **6**, 595–601 (2006).
- 638 21. Wolf, L. *et al.* IL-17A-mediated expression of epithelial IL-17C promotes inflammation
- 639 during acute Pseudomonas aeruginosa pneumonia. *American Journal of Physiology-Lung*
- 640 *Cellular and Molecular Physiology* **311**, L1015–L1022 (2016).
- 641 22. Caulfield, A. J. & Lathem, W. W. Disruption of Fas-Fas Ligand Signaling, Apoptosis, and
- 642 Innate Immunity by Bacterial Pathogens. *PLOS Pathogens* **10**, e1004252 (2014).
- 643 23. Deguine, J. & Barton, G. M. MyD88: a central player in innate immune signaling.
- 644 *F1000Prime Rep* **6**, 97 (2014).
- 645 24. Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T. & Seya, T. TICAM-1, an adaptor
- 646 molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. *Nat*
- 647 *Immunol* **4**, 161–167 (2003).
- 648 25. Sakai, J. *et al.* Lipopolysaccharide-induced NF-κB nuclear translocation is primarily
- 649 dependent on MyD88, but TNFα expression requires TRIF and MyD88. *Sci Rep* **7**, 1428
- 650 (2017).

- 651 26. Matute-Bello, G., Frevert, C. W. & Martin, T. R. Animal models of acute lung injury. Am J
- 652 *Physiol Lung Cell Mol Physiol* **295**, L379–L399 (2008).
- 653 27. Gundersen, G. W. *et al.* GEO2Enrichr: browser extension and server app to extract gene sets
- 654 from GEO and analyze them for biological functions. *Bioinformatics* **31**, 3060–3062 (2015).
- 655 28. Felciano, R. M. *et al.* Predictive systems biology approach to broad-spectrum, host-directed
- 656 drug target discovery in infectious diseases. *Pac Symp Biocomput* 17–28 (2013).
- 657 29. Aran, D. *et al.* Reference-based analysis of lung single-cell sequencing reveals a transitional
- 658 profibrotic macrophage. *Nat Immunol* **20**, 163–172 (2019).
- 659 30. Finak, G. *et al.* MAST: a flexible statistical framework for assessing transcriptional changes
- and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biology 16,
- 661 **278 (2015)**.
- 662 31. Zimmerman, K. D., Espeland, M. A. & Langefeld, C. D. A practical solution to
- 663 pseudoreplication bias in single-cell studies. *Nat Commun* **12**, 738 (2021).
- 664 32. Williams, A. E. *et al.* Evidence for chemokine synergy during neutrophil migration in ARDS.
- 665 *Thorax* **72**, 66–73 (2017).
- 666 33. Klimenkova, O. *et al.* A lack of secretory leukocyte protease inhibitor (SLPI) causes defects in
- 667 granulocytic differentiation. *Blood* **123**, 1239–1249 (2014).
- 668 34. lizuka, K. The transcription factor carbohydrate-response element-binding protein
- 669 (ChREBP): A possible link between metabolic disease and cancer. *Biochimica et Biophysica*
- 670 Acta (BBA) Molecular Basis of Disease **1863**, 474–485 (2017).
- 671 35. Sadiku, P. et al. Neutrophils Fuel Effective Immune Responses through Gluconeogenesis and
- 672 Glycogenesis. *Cell Metabolism* **33**, 411-423.e4 (2021).

- 673 36. Lawrence, T. & Natoli, G. Transcriptional regulation of macrophage polarization: enabling
- 674 diversity with identity. *Nat Rev Immunol* **11**, 750–761 (2011).
- 675 37. Zhao, C., Gillette, D. D., Li, X., Zhang, Z. & Wen, H. Nuclear factor E2-related factor-2 (Nrf2)
- 676 is required for NLRP3 and AIM2 inflammasome activation. *J Biol Chem* **289**, 17020–17029
- 677 **(2014)**.
- 678 38. Raredon, M. S. B. et al. Connectome: computation and visualization of cell-cell signaling
- 679 topologies in single-cell systems data. 2021.01.21.427529
- 680 https://www.biorxiv.org/content/10.1101/2021.01.21.427529v1 (2021)
- 681 doi:10.1101/2021.01.21.427529.
- 682 39. A draft network of ligand–receptor-mediated multicellular signalling in human | Nature
- 683 Communications. https://www.nature.com/articles/ncomms8866.
- 40. Muzio, M. *et al.* FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to
- the CD95 (Fas/APO-1) Death-Inducing Signaling Complex. *Cell* **85**, 817–827 (1996).
- 41. Tannenbaum, C. S. et al. The CXC chemokines IP-10 and Mig are necessary for IL-12-
- 687 mediated regression of the mouse RENCA tumor. *J Immunol* **161**, 927–932 (1998).
- 42. Azzam, H. S. *et al.* CD5 Expression Is Developmentally Regulated By T Cell Receptor (TCR)
- 689 Signals and TCR Avidity. *Journal of Experimental Medicine* **188**, 2301–2311 (1998).
- 690 43. Kalantar, K. L. *et al.* IDseq—An open source cloud-based pipeline and analysis service for
- 691 metagenomic pathogen detection and monitoring. *GigaScience* **9**, giaa111 (2020).
- 692 44. Mick, E. *et al.* Upper airway gene expression reveals suppressed immune responses to
- 693 SARS-CoV-2 compared with other respiratory viruses. *Nat Commun* **11**, 5854 (2020).

| 694 | 45. Paulson, J. N., Stine, O. C., Bravo, H. C. & Pop, M. Differential abundance analysis for             |
|-----|----------------------------------------------------------------------------------------------------------|
| 695 | microbial marker-gene surveys. Nat Methods 10, 1200–1202 (2013).                                         |
| 696 | 46. Panzer, A. R. et al. Lung Microbiota Is Related to Smoking Status and to Development of              |
| 697 | Acute Respiratory Distress Syndrome in Critically III Trauma Patients. Am J Respir Crit Care             |
| 698 | Med <b>197</b> , 621–631 (2018).                                                                         |
| 699 | 47. Bos, L. D. et al. Identification and validation of distinct biological phenotypes in patients        |
| 700 | with acute respiratory distress syndrome by cluster analysis. <i>Thorax</i> <b>72</b> , 876–883 (2017).  |
| 701 | 48. Morrell, E. D. et al. Alveolar Macrophage Transcriptional Programs Are Associated with               |
| 702 | Outcomes in Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 200, 732–741                  |
| 703 | (2019).                                                                                                  |
| 704 | 49. Yao, C. et al. Cell-Type-Specific Immune Dysregulation in Severely III COVID-19 Patients. Cell       |
| 705 | Reports <b>34</b> , 108590 (2021).                                                                       |
| 706 | 50. Ashley, S. L. et al. Lung and gut microbiota are altered by hyperoxia and contribute to              |
| 707 | oxygen-induced lung injury in mice. Sci Transl Med 12, (2020).                                           |
| 708 | 51. Heijnen, N. F. L. et al. Biological subphenotypes of acute respiratory distress syndrome may         |
| 709 | not reflect differences in alveolar inflammation. <i>Physiological Reports</i> <b>9</b> , e14693 (2021). |
| 710 | 52. Britton, N. et al. Diversity of the lung mycobiome is associated with severity of disease in         |
| 711 | acute respiratory distress syndrome. European Respiratory Journal 56, (2020).                            |
| 712 | 53. Sulaiman, I. et al. Microbial signatures in the lower airways of mechanically ventilated             |
| 713 | COVID-19 patients associated with poor clinical outcome. Nat Microbiol 6, 1245–1258                      |
| 714 | (2021).                                                                                                  |

- 54. Dickson, R. P. *et al.* Enrichment of the lung microbiome with gut bacteria in sepsis and the
- acute respiratory distress syndrome. *Nat Microbiol* **1**, 16113 (2016).
- 55. Camilli, G., Griffiths, J. S., Ho, J., Richardson, J. P. & Naglik, J. R. Some like it hot: Candida
- activation of inflammasomes. *PLOS Pathogens* **16**, e1008975 (2020).
- 56. Sweeney, T. E., Lofgren, S., Khatri, P. & Rogers, A. J. Gene Expression Analysis to Assess the
- 720 Relevance of Rodent Models to Human Lung Injury. *Am J Respir Cell Mol Biol* **57**, 184–192
- 721 (2017).
- 57. Altemeier, W. A. *et al.* Modulation of Lipopolysaccharide-Induced Gene Transcription and
- Promotion of Lung Injury by Mechanical Ventilation. *The Journal of Immunology* **175**, 3369–
  3376 (2005).
- 58. Bernhard, W. *et al.* Conductive airway surfactant: surface-tension function, biochemical
- 726 composition, and possible alveolar origin. *Am J Respir Cell Mol Biol* **17**, 41–50 (1997).
- 59. Kalantar, K. L. *et al.* Metagenomic comparison of tracheal aspirate and mini-bronchial
- alveolar lavage for assessment of respiratory microbiota. American Journal of Physiology-
- *Lung Cellular and Molecular Physiology* **316**, L578–L584 (2019).
- 730 60. Langelier, C. *et al.* Integrating host response and unbiased microbe detection for lower
- respiratory tract infection diagnosis in critically ill adults. *Proceedings of the National*
- 732 *Academy of Sciences* **115**, E12353 E12362 (2018).
- 733 61. ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition.
- 734 JAMA **307**, 2526–2533 (2012).

- 735 62. Horan, T. C., Andrus, M. & Dudeck, M. A. CDC/NHSN surveillance definition of health care-
- associated infection and criteria for specific types of infections in the acute care setting.
- 737 American Journal of Infection Control **36**, 309–332 (2008).
- 63. Tsitsiklis, A. *et al.* Impaired immune signaling and changes in the lung microbiome precede
- secondary bacterial pneumonia in COVID-19. *Res Sq* (2021) doi:10.21203/rs.3.rs-380803/v1.
- 740 64. Chamberlain, S. A. & Szöcs, E. taxize: taxonomic search and retrieval in R. (2013)
- 741 doi:10.12688/f1000research.2-191.v2.
- 742 65. McMurdie, P. J. & Holmes, S. phyloseq: an R package for reproducible interactive analysis
- and graphics of microbiome census data. *PLoS One* **8**, e61217 (2013).
- 744 66. Oksanen, J. *et al. vegan: Community Ecology Package*. (2020).

745

# 746 Methods

747 Patient selection

748 Subjects were selected from two prospective observational cohorts of critically ill 749 patients. The first, the Acute Lung Injury in Critical Illness study, is a cohort of mechanically 750 ventilated adults (age  $\geq$  18) admitted to the intensive care unit at the University of California. 751 San Francisco Medical Center (UCSFMC) between from July 2013 until March 2020, when 752 enrollment was paused due to the COVID-19 pandemic. The second, the COVID-19 753 Multiphenotyping for Effective Therapies (COMET) study, is a multi-omic study of hospitalized 754 patients with COVID-19 and hospitalized controls admitted to UCSFMC or Zuckerberg San 755 Francisco General Hospital (ZSFGH).

These studies were approved by the UCSF Institutional Review Board (17-24056, 20-30497), which granted an initial waiver of informed consent to collect TA and blood samples within 48 hours of ICU admission. Informed consent was then obtained from patients or surrogates, as previously described<sup>60</sup>.

760 In this analysis, we included all available subjects in each cohort who were: 1) admitted 761 to the intensive care unit for mechanical ventilation for ARDS or airway protection without 762 radiographic evidence of underlying pulmonary disease and 2) for whom we had TA sequencing 763 with at least 500,000 protein-coding counts. We reviewed PCA plots, hierarchical clustering, and 764 percentage of non-zero reads per samples for guality control and excluded four samples as 765 technical outliers. For our non-ARDS control patients, we excluded control subjects on 766 immunosuppression, including corticosteroids, and those with immunocompromising conditions 767 (HIV, chemotherapy, etc.).

768

# 769 ARDS adjudication and phenotype assignment

770 Subject charts were reviewed for ARDS adjudication by at least two study authors (AS, 771 PS, ES, FM, CL, ZL, KK, CH, MM, CC) blinded to all biological data. ARDS was diagnosed using the Berlin Definition<sup>61</sup>. Lower respiratory tract infections were diagnosed using the CDC 772 surveillance definition<sup>62</sup>. ARDS phenotype was determined using a three-variable classifier 773 774 model (IL-8, protein C, and bicarbonate) previously developed and validated for this purpose<sup>14</sup>. 775 This classifier model assigns subjects a probability of assignment to the hyperinflammatory 776 molecular phenotype identified using latent class analyses. Subjects with a probability of class 777 assignment greater than 0.5 were assigned to the hyperinflammatory class. Plasma biomarkers 778 were not available for five subjects with TA bulk RNA sequencing. For these subjects, we used 779 a validated clinical classifier model to assign phenotype.<sup>11,15</sup> 780

# 781 RNA sequencing

782 Following enrollment, TA was collected and stored in RNAse free conditions as previously described<sup>60</sup>. Metagenomic next generation sequencing (mNGS) of RNA was 783 784 performed on TA specimens using an established sequencing pipeline. Following RNA 785 extraction (Zymo Pathogen Magbead Kit) and DNase treatment, human cytosolic and 786 mitochondrial ribosomal RNA was depleted using FastSelect (Qiagen). To control for 787 background contamination, we included negative controls (water and HeLa cell RNA) as well as positive controls (spike-in RNA standards from the External RNA Controls Consortium (ERCC)). 788 789 RNA was then fragmented and underwent library preparation using the NEBNext Ultra II 790 RNASeq Kit (New England Biolabs). Libraries underwent 146 nucleotide paired-end Illumina 791 sequencing on an Illumina Novaseg 6000 instrument. 792

# 793 Host differential expression and pathway analysis

Following demultiplexing, sequencing reads were pseudo-aligned with *kallisto* (v. 0.46.1; including bias correction) to an index consisting of all transcripts associated with human protein coding genes (ENSEMBL v. 99), cytosolic and mitochondrial ribosomal RNA sequences, and the sequences of ERCC RNA standards. Gene-level counts were generated from the transcriptlevel abundance estimates using the R package *tximport*, with the scaledTPM method. Samples retained in the dataset had a total of at least 500,000 estimated counts associated with transcripts of protein coding genes, and the median across all samples was 7,528,890 counts.

801 We used an established bioinformatics pipeline to compare differential gene expression 802 in TA from hyperinflammatory and hypoinflammatory ARDS. Differential expression analysis 803 was performed using DESeg2. Gene expression was fit to a model using the design formula 804 ~Sequencing Batch + Gender + Z-scaled Age + Diagnosis. We performed pairwise comparisons 805 of 1) hyperinflammatory ARDS to hypoinflammatory ARDS, 2) all ARDS subjects to 806 mechanically ventilated controls, 3) hyperinflammatory ARDS to controls, and 4) 807 hypoinflammatory ARDS to controls. Empirical Bayesian shrinkage estimators for log<sub>2</sub>-fold 808 change were fit using apeglm. Differentially expressed genes with an independent-hypothesis 809 weighted FDR < 0.1 and absolute shrunken  $\log_2$ FoldChange greater than 0.5.

810 Differentially expressed genes were analyzed using Ingenuity Pathway Analysis (IPA, 811 Qiagen). We ran IPA Core Analyses for each pairwise comparison of differential gene 812 expression. IPA compares differentially expressed genes to a database of gene signatures 813 derived from experimental datasets. In addition to identifying signatures of canonical pathways 814 and cellular function, IPA includes a database of upstream regulators of gene function. These 815 include endogenous signaling molecules, such as cytokines, and exogenous stimuli, such as 816 drugs or toxins. The dataset also includes annotations of the relationship between regulators, 817 which can be used to construct mechanistic networks of regulators that may indirectly affect 818 gene expression. For each of the signatures, IPA calculates a p-value for the overlap of DE 819 genes with genes in the signature (using Fisher's exact test) and a z-score that tests whether 820 the measured direction of gene expression is consistent the direction in a gene signature. We 821 defined significant pathways, regulators, and networks as those with a Benjamini-Hochberg 822 false detection rate less than 0.1 or an absolute z-score greater than 2.

## 823

## 824 Single-cell RNA sequencing

TA were collected and stored at room temperature (to preserve neutrophils) and 825 826 processed within three hours as previously described<sup>63</sup>. Briefly, TA cells were isolated and 827 selected for expression of CD45, prepared with a V(D)J v1.1 kit according to the manufacturer's 828 protocol, processed on a 10x Genomics Chip A without multiplexing, and sequenced on an 829 Illumina NovaSeg 6000 platform. Because samples had to be processed shortly after collection, 830 batch processing and multiplexing were not feasible. Transcripts were aligned in Cell Ranger 831 and filtered count matrices were imported into a Seurat object. Cells were filtered to have at 832 least 300 counts, no more than 30,000 counts, and less than 10% mitochondrial genes. Cell 833 types were determined using SingleR, and the Human Primary Cell Atlas was used as the 834 annotation reference. Patients were assigned phenotypes on the basis of plasma IL-8, protein 835 C, and bicarbonate concentrations. Differential gene expression for each cell type was 836 determined using MAST, using a mixed effects model with fixed effects for phenotype and 837 cellular detection rate and a random effect for subject. Differentially expressed genes were 838 identified using Benjamini-Hochberg FDR < 0.1.

839

# 840 Plasma proteomic analysis

Plasma samples were analyzed using the O-link Proteomics Assay. This assay
generates a semi-quantitative measure of plasma protein concentrations for 96 plasma
biomarkers. We excluded all samples that were flagged with a QC warning from the O-link

platform, and excluded any biomarker where protein concentrations could not be measured for
 at least 90% of samples. Measurements for 73 of the biomarkers on the panel passed the
 manufacturer's quality control filter and were included for analysis. Normalized protein

expression measurements were compared using a Wilcoxon rank-sum test and p-values were adjusted using the Benajmini-Hochberg method (FDR < 0.1).

849

850 Comparison of differentially expressed genes to experimental models of acute lung injury 851 We selected experimental models of acute lung injury in the Gene Expression Omnibus 852 from a list of previously identified rodent and human models<sup>56</sup>. Lists of all genes differentially 853 expressed at a Benjamini-Hochberg corrected p-value less than 0.05 were downloaded using 854 GEO2Enrichr<sup>27</sup>. We then used the genes that were upregulated in the experimental lung injury 855 model as gene signatures in GSVA. If more than 200 genes were differentially expressed in the 856 experimental model, we used the top 200 genes (by p-value) for the experimental gene 857 signature. A complete list of GEO accession numbers, experimental models, and genes used in 858 each signature can be found in Supplemental Table 3A. We used limma to compare GSVA

scores in samples from each phenotype to GSVA scores in controls.

860

# 861 *Metagenomic sequencing*

FASTQ files were analyzed using IDSeg<sup>43</sup> to identify microbial reads in TA 862 863 transcriptomes. Count matrices were downloaded for tracheal samples and water controls for 864 analysis in RStudio. Taxonomic data were downloaded from NCBI using taxize<sup>64</sup>, and the matrix 865 was filtered to only include viruses, bacteria, and fungi. We fit a negative binomial model of 866 taxon-specific transcript counts against the total number of ERCC spike-in transcript reads in 867 each of the water control samples. We then used this model to predict the background 868 contamination of each taxon in each TA sample based on the number of ERCC reads. We then 869 subtracted the predicted contamination from the measured reads in the sample to estimate the 870 abundance in TA and rounded the estimate to the nearest integer. If the taxon-specific reads in 871 a TA sample were not significantly different from predicted background contamination after 872 adjusting for multiple comparisons using the Benjamini-Hochberg method, we estimated the abundance as zero. This background-corrected count matrix was used to construct a phyloseg<sup>65</sup> 873 874 object. Taxa were agglomerated at the genus level for downstream analysis.

We used estimate\_richness to calculate the Shannon diversity index for all microbial taxa, as well as subgroup analyses of bacterial and fungal genera, in TA samples. We then used vegan<sup>66</sup> to estimate the Bray-Curtis dissimilarity between samples and used adonis2 to calculate PERMANOVA p-values. We then used metagenomeSeq<sup>45</sup> to estimate differential abundance between phenotypes using zero-inflated log-normal mixture models for each genus. Normalization factors were calculated using Wrench normalization and differential abundance was estimated using fitFeatureModel.

882



| lisinopril·  |                            | $\bigcirc$ |
|--------------|----------------------------|------------|
| fluoxetine   |                            | -          |
| filgrastim   | <br> <br> <br>             |            |
| ancomycin    |                            |            |
| enalapril·   |                            |            |
| udesonide·   | •                          |            |
| rifampin ·   |                            |            |
| elumetinib · |                            |            |
| oemaciclib · |                            |            |
| imatinib-    |                            |            |
| salirasib ·  |                            |            |
| sirolimus·   |                            |            |
|              | -4 -2 (<br>IPA upstream re |            |











